Lineage Cell (Israel) Buy Hold or Sell Recommendation
| BTX Stock | ILS 218.20 1.20 0.55% |
Assuming the 90 days trading horizon and complete risk avoidance on your part, our recommendation regarding Lineage Cell Therapeutics is 'Strong Sell'. Macroaxis provides Lineage Cell buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BTX positions.
Check out Lineage Cell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Lineage and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Lineage |
Execute Lineage Cell Buy or Sell Advice
The Lineage recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lineage Cell Therapeutics. Macroaxis does not own or have any residual interests in Lineage Cell Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lineage Cell's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Lineage Cell Trading Alerts and Improvement Suggestions
| Lineage Cell generated a negative expected return over the last 90 days | |
| Lineage Cell has high historical volatility and very poor performance | |
| The company reported the revenue of 4.99 M. Net Loss for the year was (45.99 M) with profit before overhead, payroll, taxes, and interest of 4.69 M. | |
| Lineage Cell Therapeutics has accumulated about 27.1 M in cash with (30.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18. |
Lineage Cell Returns Distribution Density
The distribution of Lineage Cell's historical returns is an attempt to chart the uncertainty of Lineage Cell's future price movements. The chart of the probability distribution of Lineage Cell daily returns describes the distribution of returns around its average expected value. We use Lineage Cell Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lineage Cell returns is essential to provide solid investment advice for Lineage Cell.
| Mean Return | -0.51 | Value At Risk | -11.11 | Potential Upside | 6.97 | Standard Deviation | 5.38 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lineage Cell historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lineage Cell Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lineage Cell or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lineage Cell's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lineage stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.35 | |
β | Beta against Dow Jones | -1.47 | |
σ | Overall volatility | 5.91 | |
Ir | Information ratio | -0.12 |
Lineage Cell Volatility Alert
Lineage Cell Therapeutics exhibits very low volatility with skewness of -1.36 and kurtosis of 4.94. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Lineage Cell's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Lineage Cell's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Lineage Cell Fundamentals Vs Peers
Comparing Lineage Cell's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lineage Cell's direct or indirect competition across all of the common fundamentals between Lineage Cell and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lineage Cell or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lineage Cell's fundamental indicators could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lineage Cell to competition |
| Fundamentals | Lineage Cell | Peer Average |
| Price To Book | 1.14 X | 9.51 X |
| Price To Sales | 39.20 X | 11.42 X |
| Revenue | 4.99 M | 9.43 B |
| Gross Profit | 4.69 M | 27.38 B |
| EBITDA | (37.2 M) | 3.9 B |
| Net Income | (45.99 M) | 570.98 M |
| Cash And Equivalents | 27.1 M | 2.7 B |
| Cash Per Share | 0.18 X | 5.01 X |
| Total Debt | 5.09 M | 5.32 B |
| Debt To Equity | 3.10 % | 48.70 % |
| Current Ratio | 3.51 X | 2.16 X |
| Book Value Per Share | 1.09 X | 1.93 K |
| Cash Flow From Operations | (30.88 M) | 971.22 M |
| Number Of Employees | 76 | 18.84 K |
| Beta | 2.87 | -0.15 |
| Market Capitalization | 512.15 M | 19.03 B |
| Total Asset | 101.66 M | 29.47 B |
| Z Score | 60.0 | 8.72 |
| Net Asset | 101.66 M |
Lineage Cell Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lineage . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 2021.04 | |||
| Daily Balance Of Power | 0.0795 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 222.45 | |||
| Day Typical Price | 221.03 | |||
| Market Facilitation Index | 5.0E-4 | |||
| Price Action Indicator | (3.65) | |||
| Period Momentum Indicator | 1.2 |
About Lineage Cell Buy or Sell Advice
When is the right time to buy or sell Lineage Cell Therapeutics? Buying financial instruments such as Lineage Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lineage Cell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Cap ETFs Thematic Idea Now
Small Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 168 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Lineage Cell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.